Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.
about
Current status of immunotherapyRapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.Dasatinib promotes Th1-type responses in granzyme B expressing T-cellsSmall-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cellsResistance to c-Kit inhibitors in melanoma: insights for future therapiesRegulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity.Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator.Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.Combining cancer immunotherapy and targeted therapy.Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?Chemotherapeutic targeting of cancer-induced immunosuppressive cells.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Paradigm shift in oncology: targeting the immune system rather than cancer cells.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected DogsStrong emerging rationale for combining oncogene-targeted agents with immunotherapy.Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?Targeting tumour microenvironment by tyrosine kinase inhibitor.Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model.
P2860
Q26773314-CBCD6F53-5098-434D-BF01-1C850FFCFA29Q33404602-C7BB727C-40C3-4307-A2A2-DF7AF2694182Q33930605-1C4CB85B-509D-44B7-BE98-7E7D603D252BQ34119969-23582256-3F08-4B55-94C9-347ABD8D68A2Q34667532-E1F34A94-8603-48A1-95CF-DCA131C5CD17Q34926132-4283E19E-3560-49DE-96B6-3E3E395B8DCAQ35063621-8A35C4CD-1572-4B03-AEBB-39AD1B36D38FQ36499777-72A38C3C-CF3E-4567-8E9E-00D8A7EB1072Q36778144-964F968C-8B6B-438B-A017-97CCBE0B46DFQ37098840-4550B141-4F2B-4349-81E8-EB947E935D9DQ37698857-00525822-0D49-4C49-9D49-6A998F5F4DD1Q38081999-D924D3E0-57E3-4405-9664-CB46881DA009Q38096565-F7B85EDD-D938-4807-8890-F3F941AC5B62Q38125424-BFE64DC2-E574-42B8-BC2B-B13DB71F2C82Q38207980-2660CB35-C0D4-48EF-90BA-2FD870EF0659Q38221107-D5E27FDE-C6EA-4D74-8B00-9D535D77E32EQ38358045-675B0F8F-14E5-40FE-944E-8345D26CF950Q38374889-63B56DE9-346B-43F4-95D1-83206E24BFFDQ38636430-3019B9F9-0575-45CE-949B-CEBD90761C6AQ38947206-72D7549B-36D1-4AE3-BA9C-DFD1FE3E20F4Q41901776-070D1198-6E3B-4719-A2BC-58F769A7CBE1Q42115204-943A10DA-300C-415E-8171-2B1E917B19F5Q47136084-45C4FC64-A14C-4FA7-A321-AD47F5F4696BQ49887906-FE7ACD92-1307-4AC8-B840-8EE099FB2A6BQ50005657-F78FFDA2-8C40-460E-83BD-9B6FB330034BQ54338742-1E39678A-8421-4DE0-A071-C52FC4A617AFQ55075934-3B181101-4C35-4CC7-9163-5FB7C2492709
P2860
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antitumor T-cell responses con ...... are potentiated by anti-OX40.
@ast
Antitumor T-cell responses con ...... are potentiated by anti-OX40.
@en
type
label
Antitumor T-cell responses con ...... are potentiated by anti-OX40.
@ast
Antitumor T-cell responses con ...... are potentiated by anti-OX40.
@en
prefLabel
Antitumor T-cell responses con ...... are potentiated by anti-OX40.
@ast
Antitumor T-cell responses con ...... are potentiated by anti-OX40.
@en
P2093
P2860
P1433
P1476
Antitumor T-cell responses con ...... are potentiated by anti-OX40.
@en
P2093
Chengwen Liu
Gregory Lizée
Patrick Hwu
Scott E Woodman
Weiyi Peng
Willem W Overwijk
P2860
P304
P356
10.1182/BLOOD-2012-02-407163
P407
P577
2012-08-30T00:00:00Z